BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 18575860)

  • 1. Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia.
    Sommer C; Lackner H; Benesch M; Sovinz P; Schwinger W; Moser A; Bergloeff J; Gruber A; Urban C
    Ann Hematol; 2008 Nov; 87(11):887-90. PubMed ID: 18575860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study.
    Benesch M; Siegler N; Hoff Kv; Lassay L; Kropshofer G; Müller H; Sommer C; Rutkowski S; Fleischhack G; Urban C
    Anticancer Drugs; 2009 Oct; 20(9):794-9. PubMed ID: 19617818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation.
    Hilgendorf I; Wolff D; Junghanss C; Kahl C; Leithaeuser M; Steiner B; Casper J; Freund M
    Ann Hematol; 2008 Dec; 87(12):1009-12. PubMed ID: 18704421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis.
    Bomgaars L; Geyer JR; Franklin J; Dahl G; Park J; Winick NJ; Klenke R; Berg SL; Blaney SM
    J Clin Oncol; 2004 Oct; 22(19):3916-21. PubMed ID: 15459213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis.
    Benesch M; Sovinz P; Krammer B; Lackner H; Mann G; Schwinger W; Gadner H; Urban C
    J Pediatr Hematol Oncol; 2007 Apr; 29(4):222-6. PubMed ID: 17414563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study.
    Sancho JM; Morgades M; Arranz R; Fernández-Abellán P; Deben G; Alonso N; Blanes M; Rodríguez MJ; Nicolás C; Sánchez E; Fernández de Sevilla A; Conde E; Ribera JM;
    Med Clin (Barc); 2008 Oct; 131(11):401-5. PubMed ID: 18928719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia.
    Bassan R; Masciulli A; Intermesoli T; Audisio E; Rossi G; Pogliani EM; Cassibba V; Mattei D; Romani C; Cortelezzi A; Corti C; Scattolin AM; Spinelli O; Tosi M; Parolini M; Marmont F; Borlenghi E; Fumagalli M; Cortelazzo S; Gallamini A; Marfisi RM; Oldani E; Rambaldi A
    Haematologica; 2015 Jun; 100(6):786-93. PubMed ID: 25749825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A phase II study with high-dose cytarabine (NS-075) in adult patients with relapsed and refractory acute leukemia].
    Miyawaki S; Mizoguchi H; Tomonaga M; Kanamaru A; Tsukagoshi S; Nakamura T; Ohashi Y; Yoshida S; Ohno R
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2229-42. PubMed ID: 9881080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis.
    Sancho JM; Deben G; Parker A; Piñana JL; Bolam S; Sánchez-García E; Giménez E; Pascual T; Fernández-Abellán P; Palomera L; Ribera JM
    Int J Hematol; 2007 Jul; 86(1):33-6. PubMed ID: 17675264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytarabine dose for acute myeloid leukemia.
    Löwenberg B; Pabst T; Vellenga E; van Putten W; Schouten HC; Graux C; Ferrant A; Sonneveld P; Biemond BJ; Gratwohl A; de Greef GE; Verdonck LF; Schaafsma MR; Gregor M; Theobald M; Schanz U; Maertens J; Ossenkoppele GJ;
    N Engl J Med; 2011 Mar; 364(11):1027-36. PubMed ID: 21410371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal cytarabine in prophylaxis or curative treatment of central nervous system involvement in Burkitt leukemia/lymphoma.
    Segot A; Raffoux E; Lengline E; Thieblemont C; Dombret H; Boissel N; Cluzeau T
    Ann Hematol; 2015 Nov; 94(11):1859-63. PubMed ID: 26280395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukemia: report of 6 cases.
    Sancho JM; Ribera JM; Romero MJ; Martín-Reina V; Giraldo P; Ruiz E
    Haematologica; 2006 Mar; 91(3):ECR02. PubMed ID: 16533729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flow cytometric detection of liposomal cytarabine in cerebrospinal fluid of patients treated with intrathecal chemotherapy.
    Stacchini A; Demurtas A; Aliberti S
    Cytometry B Clin Cytom; 2012 Sep; 82(5):280-2. PubMed ID: 22539249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Central nervous system involvement in adult acute leukemia].
    Sasaki H; Maekawa I; Kawamura S; Miyake T
    Gan No Rinsho; 1984 Mar; 30(3):221-5. PubMed ID: 6585574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fulminant chemical ventriculomeningitis following intrathecal liposomal cytarabine administration.
    Butto A; Al-Holou WN; Junck L; Sagher O; Fletcher JJ
    J Clin Neurosci; 2011 Oct; 18(10):1417-8. PubMed ID: 21764318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of intrathecal liposomal cytarabine as central nervous system prophylaxis in patients with acute lymphoblastic leukemia.
    Valentin A; Troppan K; Pfeilstöcker M; Nösslinger T; Linkesch W; Neumeister P
    Leuk Lymphoma; 2014 Aug; 55(8):1739-42. PubMed ID: 24138308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers.
    Jurczak W; Kroll-Balcerzak R; Giebel S; Machaczka M; Giza A; Ogórka T; Fornagiel S; Rybka J; Wróbel T; Kumiega B; Skotnicki AB; Komarnicki M
    Med Oncol; 2015 Apr; 32(4):90. PubMed ID: 25716885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin lymphoma.
    Spina M; Chimienti E; Martellotta F; Vaccher E; Berretta M; Zanet E; Lleshi A; Canzonieri V; Bulian P; Tirelli U
    Cancer; 2010 Mar; 116(6):1495-501. PubMed ID: 20108270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrathecal liposomal cytarabine in relapsed or refractory infant and pediatric leukemias: the Children's Hospital of Philadelphia experience and review of the literature.
    Seif AE; Reilly AF; Rheingold SR
    J Pediatr Hematol Oncol; 2010 Nov; 32(8):e349-52. PubMed ID: 20962675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity and efficacy of intrathecal liposomal cytarabine in children with leukemia/lymphoma relapsing in the central nervous system: a retrospective multicenter study.
    Parasole R; Petruzziello F; Messina C; Barisone E; Pession A; Locatelli F; Micalizzi C; Cesaro S; Testi AM; De Matteo A; Varotto S; Berger M; Morello W; Menna G; Poggi V
    Leuk Lymphoma; 2015 Mar; 56(3):650-5. PubMed ID: 24882262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.